Results 51 to 60 of about 13,572 (204)

Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy

Frontiers in Oncology, 2020
Recently, targeting metabolic reprogramming has emerged as a potential therapeutic approach for fighting cancer. Sterol regulatory element binding protein-2 (SREBP-2), a basic helix-loop-helix leucine zipper transcription factor, mainly regulates genes ...
Linyuan Xue, Hongyu Qi, He Zhang, Lu Ding, Qingxia Huang, Qingxia Huang, Daqing Zhao, Boyang Jason Wu, Xiangyan Li   +8 more
doaj   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Molecular Cloning, Characterization, and Functional Analysis of Acetyl-CoA C-Acetyltransferase and Mevalonate Kinase Genes Involved in Terpene Trilactone Biosynthesis from Ginkgo biloba

Molecules, 2017
Ginkgolides and bilobalide, collectively termed terpene trilactones (TTLs), are terpenoids that form the main active substance of Ginkgo biloba. Terpenoids in the mevalonate (MVA) biosynthetic pathway include acetyl-CoA C-acetyltransferase (AACT) and ...
Qiangwen Chen, Jiaping Yan, Xiangxiang Meng, Feng Xu, Weiwei Zhang, Yongling Liao, Jinwang Qu   +6 more
doaj   +1 more source

MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway

Scientific Reports, 2022
The microRNA (miR) miR-874, a potential tumour suppressor, causes cell death via target gene suppression in various cancer types. Mevalonate pathway inhibition also causes cell death in breast cancer.
Alimasi Aersilan, Naoko Hashimoto, Kazuyuki Yamagata, Masataka Yokoyama, Akitoshi Nakayama, Xiaoyan Shi, Hidekazu Nagano, Ikki Sakuma, Nijiro Nohata, Takashi Kinoshita, Naohiko Seki, Bahityar Rahmutulla, Atsushi Kaneda, Siti Nurul Zhahara, Yingbo Gong, Motoi Nishimura, Shoichiro Kawauchi, Eiryo Kawakami, Tomoaki Tanaka   +18 more
doaj   +1 more source

Uncovering Coenzyme Q10‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program

Clinical Pharmacology &Therapeutics, EarlyView.
Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee, Yoon‐A Park, Yubin Song, Ji‐Min Han, Kyung Hee Choi, Myeong Gyu Kim, Hye Sun Gwak   +6 more
wiley   +1 more source

Identification of an Active Site Alanine in Mevalonate Kinase through Characterization of a Novel Mutation in Mevalonate Kinase Deficiency [PDF]

Journal of Biological Chemistry, 1997
Sequencing of polymerase chain reaction-amplified cDNAs from cultured cells of three patients with mevalonate kinase deficiency revealed a G --> A transversion at nucleotide 1000 of the coding region, converting alanine to threonine at position 334 (A334T).
D D, Hinson, K L, Chambliss, G F, Hoffmann, S, Krisans, R K, Keller, K M, Gibson   +5 more
openaire   +2 more sources

Bifunctional Inhibitors of Mevalonate Kinase and Mevalonate 5-Diphosphate Decarboxylase

, 2016
A bifunctional inhibitor of mevalonate kinase and mevalonate 5-diphosphate decarboxylase was synthesized. Both enzymes are in the cholesterol biosynthetic pathway and play an important role in regulating cholesterol biosynthesis.
Yongge Qiu (2647402), Ding Li (127896)
core   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra [PDF]

, 2016
Background: Mevalonate kinase deficiency is a metabolic autoinflammatory syndrome caused by mutations in the MVK gene, mevalonate kinase, the key enzyme in the non-sterol isoprenoid biosynthesis pathway. Two phenotypes of mevalonate kinase deficiency are
Birute Burnyte, Utkus, Algirdas,, Skirmante Rusoniene, Arunas Liubsys, Rymanta Gudaitiene, Nijole Drazdiene, Rusonienė, Skirmantė,, Drazdienė, Nijolė,, Algirdas Utkus, Liubšys, Arūnas,, Gudaitienė, Rymanta,, Burnytė, Birutė,, Skaiste Peciuliene, Skaiste Peciuliene, Pečiulienė, Skaistė,   +14 more
core   +1 more source

Lack of Prenylated Proteins, Autophagy Impairment and Apoptosis in SH-SY5Y Neuronal Cell Model of Mevalonate Kinase Deficiency

Cellular Physiology and Biochemistry, 2017
Background/Aims: Mevalonate Kinase Deficiency (MKD), is a hereditary disease due to mutations in mevalonate kinase gene (MVK). MKD has heterogeneous clinical phenotypes: the correlation between MVK mutations and MKD clinical phenotype is still to be ...
Paola Maura Tricarico, Alessandra Romeo, Rossella Gratton, Sergio Crovella, Fulvio Celsi   +4 more
doaj   +1 more source